- Home
- RARE vs AESI Comparison
RARE vs AESI Comparison
Compare RARE & AESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | AESI |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2013 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RARE | AESI |
|---|---|---|
| Price | $23.82 | $16.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 6 |
| Target Price | ★ $59.10 | $13.17 |
| AVG Volume (30 Days) | 1.5M | ★ 4.0M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $673,000,000.00 | ★ $1,095,310,000.00 |
| Revenue This Year | $13.12 | $2.71 |
| Revenue Next Year | $37.80 | $17.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.13 | 3.73 |
| 52 Week Low | $18.29 | $7.64 |
| 52 Week High | $40.17 | $20.13 |
Technical Indicators
Market Signals| Indicator | RARE | AESI |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 43.64 |
| Support Level | $23.69 | $10.76 |
| Resistance Level | $25.70 | $19.87 |
| Average True Range (ATR) | 1.04 | 0.96 |
| MACD | -0.26 | -0.45 |
| Stochastic Oscillator | 29.67 | 3.16 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About AESI Atlas Energy Solutions Inc.
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.